Thiamine-responsive maple syrup urine disease

Thiamine-responsive maple syrup urine disease (thiamine-responsive MSUD) is a rare variant form of maple syrup urine disease, an inherited metabolic disorder caused by deficiency of the branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. This enzyme complex is essential for the breakdown of the branched-chain amino acids (BCAAs) leucine, isoleucine, and valine. In this variant, the enzyme deficiency is partial and can be significantly improved by pharmacological doses of thiamine (vitamin B1), which serves as a cofactor for the BCKD complex. The condition primarily affects the nervous system, as accumulation of BCAAs and their corresponding ketoacids is toxic to the brain. It is classified under the intermediate forms of MSUD. Patients with thiamine-responsive MSUD typically present with a milder phenotype compared to classic MSUD. Clinical features may include developmental delay, feeding difficulties, failure to thrive, and the characteristic sweet, maple syrup-like odor of urine and body fluids due to elevated branched-chain amino acids and ketoacids. During periods of metabolic stress such as illness or fasting, patients may experience acute metabolic decompensation with encephalopathy, ataxia, lethargy, and potentially life-threatening neurological deterioration. Laboratory findings include elevated plasma leucine, isoleucine, and valine levels, along with the presence of branched-chain ketoacids in urine. Treatment centers on thiamine supplementation, typically at doses ranging from 10 to 1000 mg per day, which can substantially enhance residual BCKD enzyme activity and improve metabolic control. In addition to thiamine therapy, patients generally require dietary restriction of branched-chain amino acids to maintain safe plasma levels. Close metabolic monitoring is essential, particularly during intercurrent illness. With appropriate management including thiamine supplementation and dietary therapy, patients with this variant often have a more favorable prognosis than those with classic MSUD, though lifelong treatment and monitoring remain necessary.

Common questions about Thiamine-responsive maple syrup urine disease